Biosimilar CMC and Regulatory Challenges - New Course

Baltimore, MD
Ask a Question
Duration:  1 day
Time: 8:30 a.m. - 4:00 p.m.

Many pharmaceutical companies, both small and large, are planning or have already entered, into biosimilar manufacturing, but have a limited understanding of the Chemistry, Manufacturing & Control (CMC) comparative studies that are necessary and the challenges they will face bringing their biosimilars into market approval. An increasing number of clinical trials are being carried out for biosimilars and the number of global biosimilar market approvals all suggest a bright future for the biosimilars market in the coming years. But are biosimilars for every company?

Entering into biosimilar development is risky. The competition is stiff. The need to incorporate CMC, Nonclinical and Clinical biosimilarity into the comparability evaluation is time consuming. The regulatory pitfalls are many. Biosimilar development is definitely not as easy, or as inexpensive, as chemical generics. Before jumping into biosimilars, companies should understand the CMC and Regulatory challenges that they will face.

This course will review the regulatory challenges from a CMC perspective of biosimilars. Participants will gain an appreciation of why biosimilars are not treated by the regulatory authorities as bio-generics and will understand the totality of what is required in bringing biosimilars into the marketplace – what has worked and what has not.

Who Should Attend

This course will benefit project managers, qualified persons, directors, managers, supervisors, quality assurance personnel, quality control personnel, manufacturing personnel, regulatory affairs personnel, and any other CMC professional personnel.

More information coming soon.

Day 1

Upon completion of this course, you will be able to:

  • Explain the CMC and Regulatory challenges of biosimilar development
  • Examine case examples to effectively manage challenges faced with biosimilars
  • Apply the underlying core principles of biosimilar development, and the lessons learned, into your company’s biosimilar strategy
Agenda is subject to change.

PLEASE READ  PDA is not affiliated or contracted with any outside hotel contracting company. If someone other than PDA or the PDA chosen hotel contacts you suggesting that they represent any PDA event, they do not. It is PDA's recommendation that you book your hotel directly through the official PDA chosen hotel that is listed on our web site.

John Geigert, Ph.D., RAC, President, BioPharmaceutical Quality Solutions